Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
113.08
+1.74 (+1.56%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioNTech SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
October 15, 2024
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake
October 07, 2024
Shares peaked near 62 in late 2021, but are now worth less than half of that.
Via
Investor's Business Daily
4 Reasons Pfizer Could Be a Value Play You Can't Miss
October 07, 2024
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71
Via
MarketBeat
Exposures
COVID-19
Product Safety
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday
October 07, 2024
Via
Benzinga
Forecasting The Future: 15 Analyst Projections For BioNTech
October 07, 2024
Via
Benzinga
Forecasting The Future: 8 Analyst Projections For BioNTech
September 13, 2024
Via
Benzinga
Market Whales and Their Recent Bets on BNTX Options
September 13, 2024
Via
Benzinga
Consumer Tech News (Sept 30-Oct 4): Latest Windows 11 Update Causing Trouble, Apple Accused Of Compelling Employees To Sign Illegal Agreements & More
October 06, 2024
Major tech companies lobby against CA bill regulating AI, Apple faces legal complaints, iPhone users retain devices longer. Google warns Apple app removal.
Via
Benzinga
Topics
Artificial Intelligence
Law Enforcement
Exposures
Artificial Intelligence
Legal
Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research
October 02, 2024
This AI aims to facilitate interdisciplinary collaboration and uncover unexpected connections in scientific research.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
October 01, 2024
From
BioNTech SE
Via
GlobeNewswire
Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday
September 24, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%
Via
Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
From
BioNTech SE
Via
GlobeNewswire
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.
Via
Investor's Business Daily
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
September 17, 2024
From
BioNTech SE
Via
GlobeNewswire
Here's Why Everyone's Talking About Summit Therapeutics
September 17, 2024
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Via
The Motley Fool
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
September 16, 2024
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and...
Via
Benzinga
Exposures
COVID-19
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
September 15, 2024
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.
Via
Benzinga
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
The biotech continues to earn important wins, but is it enough?
Via
The Motley Fool
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
September 11, 2024
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...
Via
Benzinga
Why Is Moderna Stock Trading Higher On Monday?
September 09, 2024
Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu...
Via
Benzinga
Exposures
COVID-19
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
September 06, 2024
Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys.
Via
Benzinga
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
September 05, 2024
From
BioNTech SE
Via
GlobeNewswire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
From
FN Media Group LLC
Via
GlobeNewswire
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
September 03, 2024
The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for...
Via
Benzinga
Exposures
COVID-19
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
August 31, 2024
UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and...
Via
Talk Markets
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
August 29, 2024
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.